Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.00403
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Lung Brain Metastasis Pseudoprogression After Nivolumab and Ipilimumab Combination Treatment

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient With Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

Case Reports in Oncological Medicine
Oncology
2018English

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Severe Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated With Ipilimumab + Nivolumab

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Complete Remission of Metastatic Melanoma With Nivolumab and Complete Remission of Hepatitis C With Ledipasvir

Cancer therapy & Oncology International Journal
2017English

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2020English

Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab

Current Oncology
Oncology
2019English

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy